NASDAQ:ANGO - AngioDynamics Stock Price, Forecast & News

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings data on Tuesday, January, 7th. The medical instruments supplier reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.04. The medical instruments supplier had revenue of $70 million for the quarter, compared to analysts' expectations of $71.28 million. AngioDynamics had a net margin of 17.47% and a return on equity of 3.72%. The firm's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the company earned $0.22 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Tuesday, April 7th 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics issued an update on its FY20 earnings guidance on Tuesday, January, 7th. The company provided EPS guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.13. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.85 million.

1 brokerages have issued 12 month price targets for AngioDynamics' shares. Their forecasts range from $21.00 to $21.00. On average, they expect AngioDynamics' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 78.3% from the stock's current price. View Analyst Price Targets for AngioDynamics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Media headlines about ANGO stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for AngioDynamics.

AngioDynamics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,350,000 shares, an increase of 35.0% from the December 31st total of 1,000,000 shares. Based on an average daily volume of 337,900 shares, the days-to-cover ratio is presently 4.0 days. Currently, 3.7% of the company's stock are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD) and Hologic (HOLX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Oasis Petroleum (OAS), FireEye (FEYE), Intel (INTC), Mattel (MAT), Bank of America (BAC), Cal-Maine Foods (CALM), Halozyme Therapeutics (HALO), NeoGenomics (NEO) and Pattern Energy Group (PEGI).

AngioDynamics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (12.72%), Victory Capital Management Inc. (12.19%), State Street Corp (4.06%), Janus Henderson Group PLC (2.96%), Prudential Financial Inc. (1.96%) and Renaissance Technologies LLC (1.74%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Penn Capital Management Co. Inc., Geode Capital Management LLC, New York State Common Retirement Fund, Marshall Wace North America L.P., Alliancebernstein L.P., Oxford Asset Management LLP and KBC Group NV. View Insider Buying and Selling for AngioDynamics.

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Prudential Financial Inc., Bank of Montreal Can, Assenagon Asset Management S.A., Marshall Wace LLP, Renaissance Technologies LLC and State Street Corp. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $11.78.

AngioDynamics has a market capitalization of $443.23 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]